This observational study aims to understand why some prostate cancers become resistant to standard treatments (androgen-independent). Researchers believe genetics play a key role. By collecting blood samples from men with prostate cancer, they hope to identify differences in genes that might explain why some cancers are more aggressive or stop responding to anti-androgen medication. The goal is to collect blood for genetic analysis, including genomic DNA, cell-free DNA (cfDNA), and cell-free RNA (cfRNA), to link genetic variations with how prostate cancer progresses. This study is open to men aged 18 and older who have been diagnosed with prostate cancer.

Study design

This is an observational study planning to enroll 1000 participants. It involves collecting blood samples from individuals with a prior diagnosis of prostate cancer.

What's involved

You would provide blood samples, generally once for genomic DNA, with a possibility of additional samples if needed. Blood samples for cfDNA and cfRNA may be collected at multiple timepoints.

Compensation

Not stated in the trial record.

Follow-up

Genomic DNA, cfDNA, and cfRNA will be analyzed over the duration of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.